Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue.
Kelloff
Gary J
GJ
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, USA. kellofg@mail.nih.gov
Bast
Robert C
RC
Coffey
Donald S
DS
D'Amico
Anthony V
AV
Kerbel
Robert S
RS
Park
John W
JW
Ruddon
Raymond W
RW
Rustin
Gordon J S
GJ
Schilsky
Richard L
RL
Sigman
Caroline C
CC
Vande Woude
George F
GF
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D014408:Biomarkers, Tumor; D017277:Drug Approval; D015195:Drug Design; D004345:Drug Industry / Q000639:trends; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000517:prevention & control*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor